Empower Clinics and Inolife R&D Announce Letter of Intent for US Distribution Agreement for Needle-free Treatments

SEATTLE–(BUSINESS WIRE)–Empower Clinics Inc. (OTC: EPWCF) (CSE: EPW) (FRA: 8EC), a leading owner
and operator of medical cannabis and wellness clinics in the US, today
announced that it has signed a letter of intent for a national
distribution agreement with Inolife R&D, an emerging specialty medical
device company.

Under the agreement, Empower Clinics will make Inolife’s pioneering
needle-free injection devices available to patients at Empower’s 15
clinics in Oregon, Washington, and Illinois. Inolife developed its
Inojex 30 and Nanojex devices to be easy-to-use, safe, pain-free, and
more efficient in delivering treatment to patients than is possible with
traditional needle-based injections. The needle-free category has
experienced sustained double-digit growth during the past five years.

“As we continue striving to offer the most efficient and effective ways
to deliver treatment to patients, we’re very pleased to be working with
a proven leader in Inolife,” said Craig Snyder, Empower CEO. “We are
closely aligned with Inolife in terms of providing quality and
results-focused care and look forward to working with them.”

“With 15 clinics in three states, 25,000 active patients and 120,000
historic patients, Empower has a significant and growing footprint and
we are excited to further our distribution by working together,” said
Michael Wright, President & Chief Executive Officer of Inolife. “We look
forward to providing Empower and its patients with access to new and
very effective methods of administering treatment.”

Empower also announced that it has granted an aggregate of 450,000 stock
options, subject to approval of the Canadian Securities Exchange.
200,000 of such options vest immediately, are exercisable at CDN $0.26
per common share, will expire on May 25, 2023 and are otherwise governed
by the terms and conditions of the company’s stock option plan. The
remaining 250,000 options vest in 62,500 tranches on January 22, 2019,
April 22, 2019, July 22, 2019 and October 22, 2019, are exercisable at
CDN $0.26 per common share, will expire on October 22, 2023 and are
otherwise governed by the terms and conditions of the company’s stock
option plan Following the grant of the options, the company has a total
of 7,600,000 stock options outstanding representing approximately 10% of
the outstanding common shares of the company.

Empower intends to complete a non-brokered private placement 312,903
units (the “Units”) at an issuance price of CDN $0.31 per Unit for
aggregate gross proceeds of CDN $97,000. Each Unit consists of one
common share and one warrant to purchase common shares at an exercise
price of CDN $0.36 for one year from the date of issuance. The Units
issued pursuant to this private placement will be subject to a hold
period of four months and one day from the date of issuance. Empower
will also issue 517,132 Units, 1,204,851 common shares (at a deemed
issuance price of $0.2325 per share) and 423,076 common shares (at a
deemed issuance price of $0.26 per share) to settle $550,442 in
outstanding commitments of the company.


Inolife R&D Inc. is an emerging specialty medical device company focused
on developing and commercializing novel drug delivery technologies.
Inolife commercializes patented and FDA-cleared needle-free injection
devices. The company was founded to take advantage of novel techniques
of the liquid jet and ballistics-based epidermal drug injection that
improve patients’ quality of life by making medicines easier to
administer, work better, and remove the anxiety and inconvenience
associated with hypodermic needle injections. For more information about Inolife and
its products please visit www.inolifesciences.com.


Empower is a leading owner and operator of medical cannabis and wellness
clinics, as well as a developer of medical products in the US, focused
on enabling individuals to improve and protect their health. The company
provides treatment solutions through its physician-staffed clinics that
are focused on education, data, and efficacy. Empower is a recognized
leader and the first choice for patients seeking quality experience and
improved health.

For further information about Empower please see the Company’s website
at empowerclinics.com.

Certain statements included in this press release constitute
forward-looking information or statements (collectively,
“forward-looking statements”), including those identified by the
expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”,
“intend”, “may”, “should” and similar expressions to the extent they
relate to the Company or its management. Forward-looking information
contained in this news release includes, but is not limited to, the
issuance and closing of the private placement of securities and the
shares for debt transaction and the future growth plans of the
Company. The forward-looking statements are not historical facts but
reflect current expectations regarding future results or events and are
therefore based on current expectations and various estimates, factors
and assumptions and involve known and unknown risks, uncertainties and
other factors.

Neither the Canadian Securities Exchange nor the Frankfurt Stock
Exchange accepts responsibility for the adequacy or accuracy of this


Boom Capital Markets
Steve Low, 647-620-5101
[email protected]
Mark Peterson, 206-390-0204
[email protected]


Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.